Connect with us

Hi, what are you looking for?

Thursday, Dec 1, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Cannabix breathalyzer to assess intoxication in a closed course driving test experiment

The ‘comprehensive multi-analysis study’ will test the company’s FAIMS technology and its ability to detect THC in breath

Cannabix continues work on pot breathalyzer technology in Southern U.S. study this month
Photo via Cannabix Technologies.

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) will be working alongside law enforcement and toxicologists in a new study intended to assess levels of cannabis-related intoxication.

On Tuesday, the cannabis breathalyzer developer announced its participation in an upcoming research endeavour this month involving the testing of intoxicated subjects in a closed course driving test to evaluate precise levels of impairment.

Cannabix says that finer details of the study will become available once disclosure approvals are permitted to the company. The location of the new test is also unspecified at this time and the company’s devices are currently in the advanced prototype and pre-clinical testing stage.

Cannabix to continue work on pot breathalyzer tech in upcoming Southern U.S. study

Proprietary breath capture and marijuana detection equipment. Photo via Cannabix Technologies.

Read more: Cannabix study correlates THC levels in breath and blood samples

Read more: Cannabix gets third patent for its marijuana breathalyzer technology

The new study will involve testing a “supplemental version” of the company’s FAIMS technology for the detection of THC in breath samples. The analysis will also be conducted alongside other conventional drug screening methods such as oral fluid collection and blood samples.

The company has been involved in other breath-blood studies throughout 2022 in Ontario and alongside law enforcement in the southern states in June and July.

Cannabix also says it has developed a unique breath capture system capable of accurately detecting THC levels in a sample containing five breaths or less within four hours after an individual has smoked.

The company claims that studies such as these are important because they are building a body of real-world breath data from an assortment of cannabis users and that its testing technology is the most superior of its kind.

Cannabix stock increased by 8.47 per cent today to $0.32 on the Canadian Securities Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook










Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The company has also applied to trade on the OTCQB exchange


The company has sent thousands of extract vials with various cannabinoid concentrations to Germany


The government-run pot shop wants to amend limits on THC, introduce stronger QC measures and re-evaluate packaging rules


Revenue mushrooming was attributed to the company's cannabis operations and functional fungi drinks